Deepak has around 25 years of work experience with reputed companies viz. UPL Group, Teva Group, AkzoNobel India, Ranbaxy Laboratories, and Dr. Reddy’s Laboratories
The inspection was conducted from July 22-25, 2025
This partnership aims to address the growing demand for high-quality diagnostics in metropolitan areas
Upgrades 2025 full-year CDMO sales and margin outlook
Combined strength of two brands across 11 states to elevate patient care delivery and access to doctors
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date
Aims to support healthcare practitioners with evidence-based cough categorization tools that enable choosing the right molecules for effective & targeted relief from cough
This achievement underscores our unwavering commitment to upholding the highest standards of quality, safety, and regulatory compliance
Subscribe To Our Newsletter & Stay Updated
